Clinical Trials Logo

Clinical Trial Summary

This prospective, multicenter, non-interventional trial aims to study the association between TTV viral load and the occurrence of rejection or infection during the first year after transplantation. The TTV viral loads, taken once a month during the first year after the transplant, will be measured at the end of the study.


Clinical Trial Description

TTV (Torque Teno Virus) is a ubiquitous virus that is not associated with any disease. A correlation exists between the level of TTV replication and the subject's immunocompetence: weak or non-existent in immunocompetents, very high in immunocompromised patients. In heart transplant patients, pharmacological dosing of immunosuppressants prevents their toxic manifestations but is not correlated with individual immune competence. Only clinical manifestations of overdose (infections) or under dosage (rejections) currently allow optimization of immunosuppressants. A predictive biomarker of these clinical manifestations upstream of their appearance would revolutionize the management of these patients. The TTV fulfills the conditions to be an ideal biomarker: classic blood sampling, possible follow-up in all patients, low cost, carrying out the analysis on already existing molecular biology platforms, reproducibility of inter- and intra-laboratory results, defined thresholds for the reliable interpretation of the results. We believe that this marker will provide the clinician with a useful tool for the management of immunosuppressants and the patient with personalized medicine which will allow their management to be individualized. If this study confirms the expected results, then it will allow, secondly, the setting up of interventional studies to validate the TTV viral load as a biomarker, and a tool for piloting immunosuppressive treatment. The TTV viral load of heart transplant patients will be follow during the first year after transplantation. A tube of blood will be taken during the transplant and then once or twice a month. Samples will be taken at the same time as those taken as part of standard care. The TTV viral load will be measured at the end of the study. The occurrence of events of interest (infections and rejections) will be collected at each corresponding visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05064462
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Ophélie ROGIER, MSc
Phone +33 (0)1 44 84 17 89
Email [email protected]
Status Not yet recruiting
Phase
Start date October 1, 2021
Completion date October 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04973943 - Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
Recruiting NCT03477383 - A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
Recruiting NCT04707872 - Trifecta-Heart cfDNA-MMDx Study
Recruiting NCT04921774 - Research on Patients With Heart Transplantation
Recruiting NCT04226521 - Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy N/A
Completed NCT03393793 - HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Completed NCT01136135 - Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection N/A
Active, not recruiting NCT03833050 - The TOGETHER Project - Heart
Active, not recruiting NCT03373227 - Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen Phase 2
Recruiting NCT03695601 - Surveillance HeartCare® Outcomes Registry
Active, not recruiting NCT01397812 - Heartsbreath Test for Heart Transplant Rejection N/A